Pharmacokinetic and Pharmacodynamic Evaluation of P-873 versus Klebsiella pneumoniae in a Neutropenic Murine Thigh Infection Model | Zendy

Lucinda Lamb | Zendy; Jared L. Crandon | Zendy; David P. Nicolau | Zendy

Open Access

Pharmacokinetic and Pharmacodynamic Evaluation of P-873 versus Klebsiella pneumoniae in a Neutropenic Murine Thigh Infection Model

Author(s) -

Lucinda Lamb,

Jared L. Crandon,

David P. Nicolau

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02170-12

Subject(s) - klebsiella pneumoniae , pharmacodynamics , pharmacokinetics , medicine , microbiology and biotechnology , pharmacology , biology , escherichia coli , gene , biochemistry

P-873 is a novel compound in the RX-04 pyrrolocytosine series of protein synthesis inhibitors currently under development by Rib-X Pharmaceuticals. We evaluated the pharmacodynamic and pharmacokinetic properties of this compound againstKlebsiella pneumoniae using a murine neutropenic thigh infection model. P-873 demonstrated potent and rapidin vivo activity against this organism with enhanced penetration and duration of exposure in thigh tissue.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research